<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04003519</url>
  </required_header>
  <id_info>
    <org_study_id>A-DE-52030-368</org_study_id>
    <nct_id>NCT04003519</nct_id>
  </id_info>
  <brief_title>Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly</brief_title>
  <acronym>PLAN-A</acronym>
  <official_title>Non-interventional, Prospective Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to collect data about predictive factors for the efficacy of
      Lanreotide Autogel in patients with acromegaly in routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study timeline delay, low site feasibility and delay concerns due to COVID-19.
  </why_stopped>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with normalization of centrally assessed age and sex adjusted IGF-I levels at visit 4 (about 12 months) after treatment start with lanreotide autogel.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with normalization of centrally assessed age- and sex-adjusted IGF-I levels at visit 2, 3, and 5 after treatment start with lanreotide autogel</measure>
    <time_frame>3 , 6 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of centrally assessed IGF-I levels at visit 2, 3, 4, 5 after treatment start with lanreotide autogel</measure>
    <time_frame>3, 6, 12 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of centrally assessed random GH-levels at visit 2, 3, 4, 5 after treatment start with lanreotide autogel</measure>
    <time_frame>3, 6, 12 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of centrally assessed GH-BP levels at visit 2, 3, 4, 5 after treatment start with lanreotide autogel</measure>
    <time_frame>3, 6, 12 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with GH-normalization - defined as centrally assessed random GH-levels (GH &lt; 1 Î¼g/L) - at visits 2, 3, 4, and 5 during treatment with lanreotide autogel.</measure>
    <time_frame>3, 6, 12 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors for reduction of age- and sex-adjusted IGF-I to normal levels (control of acromegaly) at visits 4 compared to baseline and Last Visit Available (LVA) compared to baseline.</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of change in IGF-I between baseline compared to visit 4 and baseline compared to LVA.</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of change in random GH-levels between baseline compared to visit 4 and baseline compared to LVA</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global impression of change (PGIC)</measure>
    <time_frame>3, 6, 12 and 18 months</time_frame>
    <description>Scale is used to assess the validity of Patient Global Impression of Change (PGIC). the score ranges between 1= very much worse and 7 = very much improved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in signs and symptoms (Numerical Rating Scale), patient's global impression of change (PGIC)</measure>
    <time_frame>Baseline, 3, 6, 12 and 18 months</time_frame>
    <description>It will be measured using Numerical Rating Scale to assess the average presence or severity of the symptoms. The score ranges from 0 = no symptom at all to 10 = maximum intensity of the symptom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life between baseline and visits 2, 3, 4 and 5.</measure>
    <time_frame>Baseline, 3, 6, 12 and 18 months</time_frame>
    <description>Measured by a generic, multipurpose short-form survey with 12 questions (SF-12). Scale provides information about mental and physical functioning and overall health-related-QoL. &quot;. Higher scores indicate a better QoL.</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Acromegaly</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult subjects with biochemically active acromegaly, without previous treatment (medical
        treatment or radiotherapy) except for surgery and/or dopamine agonists (treatment
        terminated at or before baseline) who are already planned within the medical routine to be
        treated with lanreotide autogel.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 years and older with the capacity to consent

          -  Signed written informed consent

          -  Subject with hormonally active acromegaly defined by locally measured IGF-I levels 1.3
             times above the age- and sex-adjusted normal range as determined at the last routine
             visit before baseline and after surgery

          -  Subject with the intention to be treated with lanreotide autogel according to the
             current local SmPC (Germany, Austria) prior to study enrolment

        Exclusion Criteria:

          -  Participation in an interventional trial at the same time and/or within 3 months
             before baseline

          -  Subject represented by a legal guardian
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

